CTOs on the Move

Central States Health and Life Co. of Omaha

www.cso.com

 
Central States Health and Life Co. of Omaha is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.cso.com
  • 1212 N 96th St
    Omaha, NE USA 68114
  • Phone: 402.397.1111

Executives

Name Title Contact Details

Similar Companies

HumanN

No other company is more committed, or qualified, to bringing the best Nitric Oxide functional foods & supplements to every human across all phases of life.

Lumeris

Lumeris is a value-based care managed services operator for health systems and providers seeking extraordinary clinical and financial outcomes. Lumeris aligns providers and payers across populations with technologies, processes, behaviors and information to achieve high-quality, cost-effective care with satisfied consumers — and engaged physicians. Lumeris with Essence Healthcare, its inaugural client with more than 60,000 Medicare members in Missouri and Illinois, has averaged a CMS rating of 4.5 Stars for the last ten years and produced the highest consumer and physician satisfaction scores in the industry along with significantly better clinical outcomes and lower costs.

St Paul and Area Food Bank

St Paul and Area Food Bank is a St Paul, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Certara

Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. Certara`s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies.

Acucela

Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.